Annals of Surgical Oncology

, Volume 15, Issue 4, pp 962–971 | Cite as

Biology of Hepatocellular Carcinoma

  • Roberta W. C. Pang
  • Jae Won Joh
  • Philip J. Johnson
  • Morito Monden
  • Timothy M. Pawlik
  • Ronnie T. P. Poon
Hepatic and Pancreatic Tumors


Hepatocellular carcinoma (HCC) is a common cancer in the world due to high prevalence of hepatitis B or C virus infection. Research in recent years has uncovered important molecular pathways involved in development and progression of HCC. Several genetic aberrations and molecular mechanisms responsible for initiation of hepatocarcinogenesis have been identified. Novel biomarkers for HCC are being developed for better detection and prognostication. Alpha-fetoprotein, the conventional marker of HCC, has limited sensitivity and specificity. Serum levels of isoforms of AFP based on differential lectin binding of the glycan moiety appear to be more sensitive and specific than total AFP level in early detection of HCC. The clinical usefulness of other HCC biomarkers such as des-γ-carboxy prothrombin and glypican-3 are under investigation. HCC is an aggressive tumor with early vascular invasion and metastasis. Studies over the past two decades have elucidated the clinical predictors of outcome, leading to several staging systems for HCC based on clinical parameters. However, the predictive accuracy of clinical staging systems is limited. Recent studies suggested that biological factors may provide additional prognostic information. In particular, gene expression profiling appears to be a promising approach. Study of tumor angiogenesis in HCC reveals that the expression of angiogenic factors such as vascular endothelial growth factor and angiopoietins may also predict prognosis. The elucidation of tumor biology of HCC is of particular importance in the current era of rapid development of anti-cancer molecular targeting agents, which provide hope for an effective systemic therapy for HCC.


Hepatocellular Biomarkers Biological factors Angiogenesis Molecular Gene expression 


  1. 1.
    Bosch FX, Ribes J, Borras J. Epidemiology of primary liver cancer. Semin Liver Dis 1999; 3:271–85Google Scholar
  2. 2.
    Poon RT, Fan ST, Lo CM, et al. Improving survival results after resection of hepatocellular carcinoma: a prospective study of 377 patients over 10 years. Ann Surg 2001; 234:63–70PubMedGoogle Scholar
  3. 3.
    Poon RT, Fan ST, Tsang FH, et al. Locoregional therapies for hepatocellular carcinoma: a critical review from the surgeon’s perspective. Ann Surg 2002; 235:466–486PubMedGoogle Scholar
  4. 4.
    Pang R, Tse E, Poon RT. Molecular pathways in hepatocellular carcinoma. Cancer Lett 2006; 240:157–69PubMedGoogle Scholar
  5. 5.
    Brechot C, Pourcel C, Louise A, et al. Presence of integrated hepatitis B virus DNA sequences in cellular DNA of human hepatocellular carcinoma. Nature 1980; 286:533–5PubMedGoogle Scholar
  6. 6.
    Wang J, Chenivesse X, Henglein B, et al. Hepatitis B virus integration in a cyclin A gene in a hepatocellular carcinoma. Nature 1990; 343:555–7PubMedGoogle Scholar
  7. 7.
    Chami M, Gozuacik D, Saigo K, et al. Hepatitis B virus-related insertional mutagenesis implicates SERCA1 gene in the control of apoptosis. Oncogene 2000; 19:2877–86PubMedGoogle Scholar
  8. 8.
    Minami M, Daimon Y, Mori K, et al. Hepatitis B virus-related insertional mutagenesis in chronic hepatitis B patients as an early drastic genetic change leading to hepatocarcinogenesis. Oncogene 2005; 24:4340–8PubMedGoogle Scholar
  9. 9.
    Feitelson MA, Duan LX. Hepatitis B virus X antigen in the pathogenesis of chronic infections and the development of hepatocellular carcinoma. Am J Pathol 1997; 150:1141–57PubMedGoogle Scholar
  10. 10.
    Chirillo P, Falco M, Puri P, et al. Hepatitis B virus pX activates NF-kappa B-dependent transcription through a Raf-independent pathway. J Virol 1996; 700:641–6Google Scholar
  11. 11.
    Henkler F, Lopes AR, Jones M, et al. Erk-independent partial activation of AP-1 sites by the hepatitis B virus HBx protein. J Gen Virol 1998; 79:2737–42PubMedGoogle Scholar
  12. 12.
    Wang XW, Forrester K, Yeh H, et al. Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ERCC3. Proc Natl Acad Sci USA 1994; 91:2230–4PubMedGoogle Scholar
  13. 13.
    Pang R, Yuen J, Yuen MF, et al. PIN1 overexpression and beta-catenin gene mutations are distinct oncogenic events in human hepatocellular carcinoma. Oncogene 2004; 23:4182–6PubMedGoogle Scholar
  14. 14.
    Pang R, Lee TK, Poon RT, et al. Pin1 interacts with a specific Serine-Proline motif in HBx to promote hepatocarcinogenesis. Gastroenterology 2007;132:1088–103PubMedGoogle Scholar
  15. 15.
    Becker SA, Lee TH, Butel JS, et al. Hepatitis B virus X protein interferes with cellular DNA repair. J Virol 1998; 72:266–72PubMedGoogle Scholar
  16. 16.
    El-Serag HB. Epidemiology of hepatocellular carcinoma. Clin Liver Dis 2001; 5:87–207PubMedGoogle Scholar
  17. 17.
    Smela ME, Currier SS, Bailey EA, et al. The chemistry and biology of aflatoxin B(1): from mutational spectrometry to carcinogenesis. Carcinogenesis 2001; 22:535–45PubMedGoogle Scholar
  18. 18.
    Shen HM, Ong CN. Mutations of the p53 tumor suppressor gene and ras oncogenes in aflatoxin hepatocarcinogenesis. Mutat Res 1996; 366:23–44PubMedGoogle Scholar
  19. 19.
    Bressac B, Kew M, Wands J, et al. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature 1991; 350:429–31PubMedGoogle Scholar
  20. 20.
    Sell S, Hunt JM, Dunsford HA, et al. Synergy between hepatitis B virus expression and chemical hepatocarcinogens in transgenic mice. Cancer Res 1991; 51:1278–85PubMedGoogle Scholar
  21. 21.
    Ghebranious N, Sell S. The mouse equivalent of the human p53ser249 mutation p53ser246 enhances aflatoxin hepatocarcinogenesis in hepatitis B surface antigen transgenic and p53 heterozygous null mice. Hepatology 1998; 27:967–73PubMedGoogle Scholar
  22. 22.
    Kwun HJ, Jung EY, Ahn JY, et al. p53-dependent transcriptional repression of p21(waf1) by hepatitis C virus NS3. J Gen Virol 2001; 82:2235–41PubMedGoogle Scholar
  23. 23.
    Ghosh AK, Steele R, Meyer K, et al. Hepatitis C virus NS5A protein modulates cell cycle regulatory genes and promotes cell growth. J Gen Virol 1999; 80:1179–83PubMedGoogle Scholar
  24. 24.
    Lee MN, Jung EY, Kwun HJ, et al. Hepatitis C virus core protein represses the p21 promoter through inhibition of a TGF-beta pathway. J Gen Virol 2002; 83:2145–51PubMedGoogle Scholar
  25. 25.
    Ray RB, Lagging LM, Meyer K, et al. Transcriptional regulation of cellular and viral promoters by the hepatitis C virus core protein. Virus Res 1995; 37:209–20PubMedGoogle Scholar
  26. 26.
    Moriya K, Fujie H, Shintani Y, et al. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med 1998; 4:1065–7PubMedGoogle Scholar
  27. 27.
    Marusawa H, Hijikata M, Chiba T, et al. Hepatitis C virus core protein inhibits Fas- and tumor necrosis factor alpha-mediated apoptosis via NF-kappaB activation. J Virol 1999; 73:4713–20PubMedGoogle Scholar
  28. 28.
    Yeh CN, Lee WC, Chen MF. Hepatic resection and prognosis for patients with hepatocellular carcinoma larger than 10 cm: two decades of experience at Chang Gung memorial hospital. Ann Surg Oncol 2003; 10:1070–6PubMedGoogle Scholar
  29. 29.
    O’Suilleabhain CB, Poon RT, Yong JL, et al. Factors predictive of 5-year survival after transarterial chemoembolization for inoperable hepatocellular carcinoma. Br J Surg 2003; 90:325–31PubMedGoogle Scholar
  30. 30.
    Johnson PJ, Williams R. Serum alpha-fetoprotein estimations and doubling time in hepatocellular carcinoma: Influence of therapy and possible value in early detection. J Nat Cancer Inst 1980; 64:1329–32PubMedGoogle Scholar
  31. 31.
    Johnson PJ. The role of serum alpha-fetoprotein estimation in the diagnosis and management of hepatocellular carcinoma. Clinics in Liver Disease, ed. Di Bisceglie A. WB Saunders, Philadelphia, 2001; 5:p145–59Google Scholar
  32. 32.
    Sherman M. Alphafetoprotein: an obituary. J Hepatol 2001; 34:603–5PubMedGoogle Scholar
  33. 33.
    Zhou L, Liu J, Luo F. Serum tumor markers for detection of hepatocellular carcinoma. World J Gastroenterol 2006; 12:1175–81PubMedGoogle Scholar
  34. 34.
    Li D, Mallory T, Satomura S. AFP-L3: a new generation of tumor marker for hepatocellular carcinoma. Clin Chim Acta 2001; 313:15–9PubMedGoogle Scholar
  35. 35.
    Yuen MF, Lai CL. Serological markers of liver cancer. Best Pract Res Clin Gastroenterol 2005; 19:91–9PubMedGoogle Scholar
  36. 36.
    Johnson PJ, Poon TCW, Hjelm NM, et al. Glycan composition of serum alpha-fetoprotein in patients with hepatocellular carcinoma and non-seminomatous germ cell tumour. Br J Cancer 1999; 81:1188–95PubMedGoogle Scholar
  37. 37.
    Johnson PJ, Poon TC, Hjelm NM, et al. Structures of disease-specific serum alpha-fetoprotein isoforms. Br J Cancer 2000; 83:1330–7. PubMedGoogle Scholar
  38. 38.
    Johnson PJ, Leung N, Cheng P, et al. “Hepatoma-specific” alphafetoprotein may permit preclinical diagnosis of malignant change in patients with chronic liver disease. Br J Cancer 1997; 75:236–40. PubMedGoogle Scholar
  39. 39.
    Poon TC, Mok TS, Chan AT, et al. Quantification and utility of monosialylated alpha-fetoprotein in the diagnosis of hepatocellular carcinoma with nondiagnostic serum total alpha-fetoprotein. Clin Chem 2002; 48:1021–7PubMedGoogle Scholar
  40. 40.
    Taketa K, Endo Y, Sekiya C, et al. A collaborative study for the evaluation of lectin-reactive alpha-fetoprotein in early detection of hepatocellular carcinoma. Cancer Res 1993; 53:5419–23PubMedGoogle Scholar
  41. 41.
    Hayashi K, Kumada T, Nakano S, et al. Usefulness of measurement of Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein as a marker of prognosis and recurrence of small hepatocellular carcinoma. Am J Gastroenterol 1999; 94:3028–33PubMedGoogle Scholar
  42. 42.
    Ono M, Ohat H, Ohhira M. Measurement of immunoreactive prothrombin precursor and vitamin-K dependent gamma-carboxylation in human hepatocellular tissues: decreased carboxylation of prothrombin precursor as a cause of des-gamma-carboxyprothrombin synthesis. Tumour Biol 1990; 11:319–26PubMedGoogle Scholar
  43. 43.
    Weitz IC, Liebman HA. Dex-gamma-carboxy (abnormal) prothrombin and hepatocellular carcinoma. Hepatology 1993; 18:990–7PubMedGoogle Scholar
  44. 44.
    Nomura F, Ishijima M, Horikoshi A, et al. Determination of serum des-gamma-carboxyprothrombin levels in patients with small-sized hepatocellular carcinoma. Comparison of the conventional enzyme immunoassay and two modified methods. Am J Gastroenterol 1996; 91:1380–3PubMedGoogle Scholar
  45. 45.
    Shimauchi Y, Tanaka M, Kuromatsu R, et al. A simultaneous monitoring of Lens culinaris agglutinin A-reactive alpha-fetoprotein and des-gamma-carboxy prothrombin as an early diagnosis of hepatocellular carcinoma in the follow-up of cirrhotic patients. Oncol Rep 2000; 7:249–56PubMedGoogle Scholar
  46. 46.
    Ishii M, Gama H, Chida N, et al. Simultaneous measurements of serum alpha-fetoprotein and protein induced by vitamin K absence for detecting hepatocellular carcinoma. South Tohoku District Study Group. Am J Gastroenterol 2000; 95:1036–40PubMedGoogle Scholar
  47. 47.
    Okuda H, Nakanishi T, Takatsu K et al. Comparison of clinicopathological features of patients with hepatocellular carcinoma seropositive for alpha-fetoprotein alone and those seropositive for des-gamma-carboxy prothrombin alone. J Gastroenterol Hepatol 2001; 16:1290–6. PubMedGoogle Scholar
  48. 48.
    Hamamura K, Shiratori Y, Shiina S, et al. Unique clinical characteristics of patients with hepatocellular carcinoma who present with high plasma des-gamma-carboxy prothrombin and low serum alpha-fetoprotein. Cancer 2000; 88:1557–64. PubMedGoogle Scholar
  49. 49.
    Filmus J, Selleck SB. Glypicans: proteoglycans with a surprise. J Clin Invest 2001; 108:497–501PubMedGoogle Scholar
  50. 50.
    Nakatsura T, Yoshitake Y, Senju S, et al. Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker. Biochem Biophys Res Commun 2003; 306:16–25PubMedGoogle Scholar
  51. 51.
    Capurro M, Wanless IR, Sherman M, et al. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology 2003; 125:89–97PubMedGoogle Scholar
  52. 52.
    Hippo Y, Watanabe K, Watanabe A, et al. Identification of soluble NH2-terminal fragment of glypican-3 as a serological marker for early-stage hepatocellular carcinoma. Cancer Res 2004; 64:2418–23. PubMedGoogle Scholar
  53. 53.
    Cheung ST, Wong SY, Leung KL, et al. Granulin-epithelin precursor overexpression promotes growth and invasion of hepatocellular carcinoma. Clin Cancer Res 2004; 10:7629–36PubMedGoogle Scholar
  54. 54.
    Poon TC, Yip TT, Chan AT, et al. Comprehensive proteomic profiling identifies serum proteomic signatures for detection of hepatocellular carcinoma and its subtypes. Clin Chem 2003; 49:752–60. PubMedGoogle Scholar
  55. 55.
    Schwegler EE, Cazares L, Steel LF, et al. SELDI-TOF MS profiling of serum for detection of the progression of chronic hepatitis C to hepatocellular carcinoma. Hepatology 2005; 41:634–42. PubMedGoogle Scholar
  56. 56.
    Ward DG, Cheng Y, N’kontchou G, et al. Preclinical and post-treatment changes in the HCC-associated serum proteome. Br J Cancer 2006; 95:1379–83. PubMedGoogle Scholar
  57. 57.
    Belghiti J, Panis Y, Farges O, et al. Intrahepatic recurrence after resection of hepatocellular carcinoma complicating cirrhosis. Ann Surg 1991; 214:114–7PubMedGoogle Scholar
  58. 58.
    Poon RT, Fan ST, Lo CM, et al. Intrahepatic recurrence after curative resection of hepatocellular carcinoma: long-term results of treatment and prognostic factors. Ann Surg 1999; 229:216–22PubMedGoogle Scholar
  59. 59.
    Klintmalm GB. Liver transplantation for hepatocellular carcinoma: a registry report of the impact of tumor characteristics on outcome. Ann Surg 1998; 228:479–90PubMedGoogle Scholar
  60. 60.
    Marsh JW, Dvorchik I, Subotin M, et al. The prediction of risk of recurrence and time to recurrence of hepatocellular carcinoma after orthotopic liver transplantation: a pilot study. Hepatology 1997; 26:444–50PubMedGoogle Scholar
  61. 61.
    Izumi R, Shimizu K, Ii T et al. Prognostic factors of hepatocellular carcinoma in patients undergoing hepatic resection. Gastroenterology 1994; 106:720–7PubMedGoogle Scholar
  62. 62.
    Yamanaka N, Okamoto E, Toyosaka A, et al. Prognostic factors after hepatectomy for hepatocellular carcinomas. A univariate and multivariate analysis. Cancer 1990; 65:1104–10PubMedGoogle Scholar
  63. 63.
    The Liver Cancer Study Group of Japan. Predictive factors for long term prognosis after partial hepatectomy for patients with hepatocellular carcinoma in Japan. Cancer 1994; 74:2772–80Google Scholar
  64. 64.
    A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology 1998; 28:751–5Google Scholar
  65. 65.
    Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999; 19:329–38PubMedCrossRefGoogle Scholar
  66. 66.
    Liver (Including intrahepatic bile ducts). In: Green F, Page D, I. F, et al, eds. AJCC Cancer Staging Handbook. New York: Springer; 2002:131–44Google Scholar
  67. 67.
    Kawarada Y, Ito F, Sakurai H, et al. Surgical treatment of hepatocellular carcinoma. Cancer Chemother Pharmacol 1994; 33 Suppl:S12–7Google Scholar
  68. 68.
    Pawlik TM, Poon RT, Abdalla EK, et al. Critical appraisal of the clinical and pathologic predictors of survival after resection of large hepatocellular carcinoma. Arch Surg 2005; 140:450–7. PubMedGoogle Scholar
  69. 69.
    Kosuge T, Makuuchi M, Takayama T, et al. Long-term results after resection of hepatocellular carcinoma: experience of 480 cases. Hepatogastroenterology 1993; 40:328–32PubMedGoogle Scholar
  70. 70.
    Poon RT, Fan ST, Wong J. Selection criteria for hepatic resection in patients with large hepatocellular carcinoma larger than 10 cm in diameter. J Am Coll Surg 2002; 194:592–602PubMedGoogle Scholar
  71. 71.
    Pawlik TM, Delman KA, Vauthey JN, et al. Tumor size predicts vascular invasion and histologic grade: Implications for selection of surgical treatment for hepatocellular carcinoma. Liver Transpl 2005; 11:1086–92PubMedGoogle Scholar
  72. 72.
    Tsai TJ, Chau GY, Lui WY, et al. Clinical significance of microscopic tumor venous invasion in patients with resectable hepatocellular carcinoma. Surgery 2000; 127:603–8PubMedGoogle Scholar
  73. 73.
    Jonas S, Bechstein WO, Steinmuller T, et al. Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology 2001; 33:1080–6PubMedGoogle Scholar
  74. 74.
    Vauthey JN, Klimstra D, Franceschi D, et al. Factors affecting long-term outcome after hepatic resection for hepatocellular carcinoma. Am J Surg 1995; 169:28–34PubMedGoogle Scholar
  75. 75.
    Ng KK, Vauthey JN, Pawlik TM, et al. Is hepatic resection for large or multinodular hepatocellular carcinoma justified? Results from a multi-institutional database. Ann Surg Oncol 2005; 12:364–73PubMedGoogle Scholar
  76. 76.
    Vauthey JN, Lauwers GY, Esnaola NF et al. Simplified staging for hepatocellular carcinoma. J Clin Oncol 2002; 20:1527–36PubMedGoogle Scholar
  77. 77.
    Ikai I, Yamamoto Y, Yamamoto N, et al. Results of hepatic resection for hepatocellular carcinoma invading major portal and/or hepatic veins. Surg Oncol Clin North Am 2003; 12:65–75Google Scholar
  78. 78.
    Pawlik TM, Poon RT, Abdalla EK, et al. Hepatectomy for hepatocellular carcinoma with major portal or hepatic vein invasion: results of a multicenter study. Surgery 2005; 137:403–10PubMedGoogle Scholar
  79. 79.
    Poon RT, Fan ST, Wong J. Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma. Ann Surg 2000; 232:10–24. Google Scholar
  80. 80.
    Murgita RA, Goidl EA, Kontianen S, et al. Alpha-Fetoprotein induces suppressor T cells in vitro. Nature 1977; 267:257–9PubMedGoogle Scholar
  81. 81.
    Yachnin S, Soltani K, Lester EP. Further studies on the mechanism of suppression of human lymphocyte transformation by human alpha fetoprotein. J Allergy Clin Immunol 1980; 65:127–35PubMedGoogle Scholar
  82. 82.
    Shirabe K, Shimada M, Kajiyama K, et al. Clinicopathologic features of patients with hepatocellular carcinoma surviving >10 years after hepatic resection. Cancer 1998; 83:2312–6PubMedGoogle Scholar
  83. 83.
    Bilimoria MM, Lauwers GY, Doherty DA, et al. Underlying liver disease, not tumor factors, predicts long-term survival after resection of hepatocellular carcinoma. Arch Surg 2001; 136:528–35PubMedGoogle Scholar
  84. 84.
    Yamanaka N, Tanaka T, Tanaka W, et al. Correlation of hepatitis virus serologic status with clinicopathologic features in patients undergoing hepatectomy for hepatocellular carcinoma. Cancer 1997; 79:1509–15PubMedGoogle Scholar
  85. 85.
    Haratake J, Takeda S, Kasai T, et al. Predictable factors for estimating prognosis of patients after resection of hepatocellular carcinoma. Cancer 1993; 72:1178–83PubMedGoogle Scholar
  86. 86.
    Pawlik TM, Poon RT, Abdalla EK, et al. Hepatitis serology predicts tumor and liver-disease characteristics but not prognosis after resection of hepatocellular carcinoma. J Gastrointest Surg 2004; 8:794–804PubMedGoogle Scholar
  87. 87.
    Ntzani EE, Ioannidis JPA. Predictive ability of DNA microarrays for cancer outcomes and correlates: an empirical assessment. Lancet 2003; 362:1439–44PubMedGoogle Scholar
  88. 88.
    Chiu JH, Kao HL, Wu LH, et al. Prediction of relapse or survival after resection in human hepatomas by DNA flow cytometry. J Clin Invest 1992; 89:539–45PubMedGoogle Scholar
  89. 89.
    Ng IOL, Lai ECS, Fan ST, et al. Prognostic significance of proliferating cell nuclear antigen expression in hepatocellular carcinoma. Cancer 1994; 73:2268–74PubMedGoogle Scholar
  90. 90.
    Suda T, Isokawa O, Aoyagi Y, et al. Quantitation of telomerase activity in hepatocellular carcinoma: a possible aid for a prediction of recurrent diseases in the remnant liver. Hepatology 1998; 27:402–6PubMedGoogle Scholar
  91. 91.
    Hayashi H, Sugio K, Matsumata T, et al. The clinical significance of p53 gene mutation in hepatocellular carcinoma from Japan. Hepatology 1995; 22:1702–7PubMedGoogle Scholar
  92. 92.
    Ye QH, Qin LX, Forgues M, et al. Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med 2003; 9:416–23PubMedGoogle Scholar
  93. 93.
    Iizuka N, Oka M, Yamada-Okabe H, et al. Oligonucleotide microarray for prediction of early intrahepatic recurrence of hepatocellular carcinoma after curative resection. Lancet 2003; 361:923–9PubMedGoogle Scholar
  94. 94.
    Lee JS, Chu IS, Heo J, et al. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology 2004; 40:667–76. PubMedGoogle Scholar
  95. 95.
    Kurokawa Y, Matoba R, Takemasa I, et al. Molecular-based prediction of early recurrence in hepatocellular carcinoma. J Hepatol 2004; 41:284–91. PubMedGoogle Scholar
  96. 96.
    Kurokawa Y, Matoba R, Nagano H, et al. Molecular prediction of response to 5-fluorouracil and interferon-alpha combination chemotherapy in advanced hepatocellular carcinoma. Clin Cancer Res 2004; 10:6029–38PubMedGoogle Scholar
  97. 97.
    Lee JS, Thorgeirsson SS. Comparative and integrative functional genomics of HCC. Oncogene 2006; 25:3801–9PubMedGoogle Scholar
  98. 98.
    Cheung ST, Chen XY, Guan XY, et al. Identify metastasis-associated genes in hepatocellular carcinoma through clonality delineation for multinodular tumor. Cancer Res 2002; 62:4711–21PubMedGoogle Scholar
  99. 99.
    Smith MW, Yue ZN, Geiss GK, et al. Identification of novel tumor markers in hepatitis C virus-associated hepatocellular carcinoma. Cancer Res 2003; 63:859–64PubMedGoogle Scholar
  100. 100.
    Patil MA, Chua MS, Oan KH, et al. An integrated data analysis approach to characterize genes highly expressed in hepatocellular carcinoma. Oncogene 2005; 24:3737–47PubMedGoogle Scholar
  101. 101.
    Yao DF, Wu XH, Zhu Y, et al. Quantitative analysis of vascular endothelial growth factor, microvascular density and their clinicopathologic features in human hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2005; 4:220–6PubMedGoogle Scholar
  102. 102.
    Poon RT, Ng IO, Lau C, et al. Tumor microvessel density as a predictor of recurrence after resection of hepatocellular carcinoma: a prospective study. J Clin Oncol 2002; 20:1775–85PubMedGoogle Scholar
  103. 103.
    Sun HC, Tang ZY, Li XM, et al. Microvessel density of hepatocellular carcinoma: its relationship with prognosis. Cancer Res Clin Oncol 1999; 125:419–26Google Scholar
  104. 104.
    Uemori EN, Ferrara N, Bauer EA, et al. Vascular endothelial growth factor induces interstitial collagenase in human endothelial cells. J Cell Physiol 1992; 153:557–62Google Scholar
  105. 105.
    Poon RT, Fan ST, Wong J. Clinical implications of circulating angiogenic factors in cancer patients. J Clin Oncol 2001; 19:1207–25PubMedGoogle Scholar
  106. 106.
    Chow NH, Hsu PI, Lin XZ, et al. Expression of vascular endothelial growth factor in normal liver and hepatocellular carcinoma: an immunohistochemical study. Hum Pathol 1997; 28:698–703PubMedGoogle Scholar
  107. 107.
    Li XM, Tang ZY, Zhou G, et al. Significance of vascular endothelial growth factor mRNA expression in invasion and metastasis of hepatocellular carcinoma. J Exp Clin Cancer Res 1998; 17:13–17PubMedGoogle Scholar
  108. 108.
    Poon RT, Ng IO, Lau C, et al. Serum vascular endothelial growth factor predicts venous invasion in hepatocellular carcinoma: a prospective study. Ann Surg 2001; 233:227–35PubMedGoogle Scholar
  109. 109.
    Poon RT, Ho JW, Tong CS, et al. Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma. Br J Surg 2004; 91:1354–60PubMedGoogle Scholar
  110. 110.
    Ho J, Pang RW, Lau C, et al. Significance of circulating endothelial progenitor cells in hepatocellular carcinoma. Hepatology 2006; 44:836–43PubMedGoogle Scholar
  111. 111.
    Shimamura T, Saito S, Morita K, et al. Detection of vascular endothelial growth factor and its receptor expression in human hepatocellular carcinoma biopsy specimens. J Gastroenterol Hepatol 2000; 15:640–6PubMedGoogle Scholar
  112. 112.
    El-Assal ON, Yamanoi A, Soda Y, et al. Clinical significance of microvessel density and vascular endothelial growth factor expression in hepatocellular carcinoma and surrounding liver: possible involvement of vascular endothelial growth factor in the angiogenesis of cirrhotic liver. Hepatology 1998; 27:1554–62PubMedGoogle Scholar
  113. 113.
    Holash J, Wiegand SJ, Yancopoulos GD. New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF. Oncogene 1999; 18:5356–62PubMedGoogle Scholar
  114. 114.
    Mituha N, Shimizu N, Ohtsuka M, et al. Angiopoietins and Tie-2 expression in angiogenesis and proliferation of human hepatocellular carcinoma. Hepatology 2003; 37:1105–13Google Scholar
  115. 115.
    Zhang ZL, Liu ZS, Sun Q. Expression of angiopoietins, Tie2 and vascular endothelial growth factor in angiogenesis and progression of hepatocellular carcinoma. World J Gastroenterol 2006; 12:4241–5PubMedGoogle Scholar
  116. 116.
    Tanaka S, Sugimachi K, Yamashita Y. Tie2 vascular endothelial receptor expression and function in hepatocellular carcinoma. Hepatology 2002; 35:861–7PubMedGoogle Scholar
  117. 117.
    El-Assal ON, Yamanoi A, Ono T, et al. The clinicopathological significance of heparanase and basic fibroblast growth factor expressions in hepatocellular carcinoma, Clin Cancer Res 2001; 7:1299–305PubMedGoogle Scholar
  118. 118.
    Morinaga S, Yamamoto Y, Noguchi Y, et al. Platelet-derived endothelial cell growth factor (PD-ECGF) is up-regulated in human hepatocellular carcinoma (HCC) and the corresponding hepatitis liver. Hepatogastroenterology 2003; 50:1521–6PubMedGoogle Scholar
  119. 119.
    Poon RT, Lau CP, Ho J, et al. Tissue factor expression correlates with tumor angiogenesis and invasiveness in human hepatocellular carcinoma. Clin Cancer Res 2003; 9:5339–45PubMedGoogle Scholar
  120. 120.
    Tang TC, Poon RT, Lau CP, et al. Tumor cyclooxygenase-2 levels correlate with tumor invasiveness in human hepatocellular carcinoma. World J Gastroenterol 2005; 11:1896–902PubMedGoogle Scholar
  121. 121.
    Hisai H, Kato J, Kobune M, et al. Increased expression of angiogenin in hepatocellular carcinoma in correlation with tumor vascularity. Clin Cancer Res 2003; 9:4852–9PubMedGoogle Scholar
  122. 122.
    Pang R, Poon RT. Angiogenesis and antiangiogenic therapy in hepatocellular carcinoma. Cancer Lett 2006; 242:151–67PubMedGoogle Scholar

Copyright information

© Society of Surgical Oncology 2007

Authors and Affiliations

  • Roberta W. C. Pang
    • 1
  • Jae Won Joh
    • 2
  • Philip J. Johnson
    • 3
  • Morito Monden
    • 4
  • Timothy M. Pawlik
    • 5
  • Ronnie T. P. Poon
    • 1
  1. 1.Centre for Cancer ResearchThe University of Hong KongHong KongChina
  2. 2.Department of Surgery, Samsung Medical CenterSungkyunkwan University School of MedicineSeoulKorea
  3. 3.Cancer Research UK Institute for Cancer StudiesThe University of BirminghamBirminghamUK
  4. 4.Department of SurgeryOsaka University, Graduate School of MedicineOsakaJapan
  5. 5.Department of SurgeryJohn Hopkins School of MedicineBaltimoreUSA

Personalised recommendations